About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Shareholders
Corporate Presentation
Financial Calendar
Regulated Information
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
R&D Day
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Financial | Nanobiotix Revenue Q3 2015
Scientific Clinical | Nanobiotix’s Soft Tissue Sarcoma pivotal trial progressing well as planned: already 7 countries and 29 sites opened
13 November 2015
Scientific Clinical | FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer
4 January 2016
Financial | Nanobiotix Revenue Q3 2015
Published by
adminvl
on
13 November 2015
No translations available for this page
